- Home
- Publications
- Publication Search
- Publication Details
Title
Toxicities associated with checkpoint inhibitors—an overview
Authors
Keywords
-
Journal
RHEUMATOLOGY
Volume 58, Issue Supplement_7, Pages vii7-vii16
Publisher
Oxford University Press (OUP)
Online
2019-08-30
DOI
10.1093/rheumatology/kez418
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
- (2019) Iosune Baraibar et al. DRUG SAFETY
- Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors
- (2018) Merav Lidar et al. AUTOIMMUNITY REVIEWS
- Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1
- (2018) Ahmed Mekki et al. EUROPEAN JOURNAL OF CANCER
- Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective
- (2018) Dipti M Karamchandani et al. JOURNAL OF CLINICAL PATHOLOGY
- Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barré syndrome
- (2018) Takamasa Nukui et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Toxicity profiles of immunotherapy
- (2018) S. Cousin et al. PHARMACOLOGY & THERAPEUTICS
- Uveal Effusion After Immune Checkpoint Inhibitor Therapy
- (2018) Merina Thomas et al. JAMA Ophthalmology
- Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
- (2018) Mehdi Touat et al. NEUROLOGY
- Predictors of immunotherapy-induced immune-related adverse events
- (2018) A. Kartolo et al. Current Oncology
- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
- (2017) Ralf Gutzmer et al. EUROPEAN JOURNAL OF CANCER
- Immune-related bone marrow failure following anti-PD1 therapy
- (2017) Jean-Marie Michot et al. EUROPEAN JOURNAL OF CANCER
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- (2017) Myriam Delaunay et al. EUROPEAN RESPIRATORY JOURNAL
- Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient
- (2017) Hiroaki Kanno et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors
- (2017) Sophie Feng et al. Journal of Thoracic Oncology
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
- (2017) David J. Byun et al. Nature Reviews Endocrinology
- Myasthenia triggered by immune checkpoint inhibitors: New case and literature review
- (2017) Natalia L. Gonzalez et al. NEUROMUSCULAR DISORDERS
- Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
- (2017) Jarushka Naidoo et al. ONCOLOGIST
- A Case of Immune Thrombocytopenia as a Rare Side Effect of an Immunotherapy with PD1-Blocking Agents for Metastatic Melanoma
- (2017) Claudia Pföhler et al. TRANSFUSION MEDICINE AND HEMOTHERAPY
- Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis
- (2017) Animesh Jain et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- Nivolumab-induced aplastic anemia: A case report and literature review
- (2017) Rachel R Comito et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
- (2017) Benjamin L. Maughan et al. Frontiers in Oncology
- The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
- (2016) B. Lee et al. ANNALS OF ONCOLOGY
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
- (2016) Laura C Cappelli et al. ANNALS OF THE RHEUMATIC DISEASES
- Acute interstitial nephritis related to immune checkpoint inhibitors
- (2016) Julie Belliere et al. BRITISH JOURNAL OF CANCER
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’
- (2016) Raul S Gonzalez et al. HISTOPATHOLOGY
- Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain–Barré syndrome: a case report
- (2016) Ryota Tanaka et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient
- (2016) Takashi Arai et al. JOURNAL OF DERMATOLOGY
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
- (2016) Frank B. Cortazar et al. KIDNEY INTERNATIONAL
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy in patients with preexisting autoimmune disorders
- (2016) Marco Donia et al. Seminars in Immunopathology
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
- (2016) Tanya J. Williams et al. JAMA Neurology
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis
- (2016) Zhijuan Lin et al. PLoS One
- Systematic review: colitis associated with anti-CTLA-4 therapy
- (2015) A. Gupta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kidney injuries related to ipilimumab
- (2014) Hassane Izzedine et al. INVESTIGATIONAL NEW DRUGS
- Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma
- (2014) Evan J. Lipson et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice
- (2014) J. A. Lucas et al. JOURNAL OF IMMUNOLOGY
- Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
- (2014) Edward J Gettings et al. Multiple Sclerosis Journal
- Ipilimumab-Associated Colitis: CT Findings
- (2013) Kyung Won Kim et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- α-CTLA-4 mAb-associated Panenteritis
- (2009) Darryl A. Oble et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started